In response to today's news regarding clinical trials of GLP-1s for use in psoriasis, Zest Dermatology's leadership shares the following insights:
Olivia Deitcher, CEO: "Psoriasis medications maintain strong formulary coverage despite high price tags. GLP-1 sponsors are clearly eyeing this market dynamic, perhaps to drive better coverage of their products. With our existing partners and beyond, Zest is well positioned to collaborate with health plans and employers to navigate the best path forward."
Rachel Day MD, FAAD, VP of Clinical: "As a dermatologist, I’m encouraged by the progress in understanding the systemic impact of psoriasis, including its links to cardiovascular disease and metabolic dysfunction. These conditions drive inflammation and contribute to overall health risks. However, I’m concerned that healthcare often prioritizes pharmaceutical solutions over lower-cost, effective interventions like diet and exercise, despite evidence supporting their benefits in psoriasis management. For instance, a 2014 randomized controlled study demonstrated significant improvement with a dietetic intervention and a recent review of nutrition as a therapeutic tool for psoriasis supported nutrition as a therapeutic intervention. I'll be closely following the emerging GLP-1 data."
Madison Muller Bloomberg News
📰 https://lnkd.in/g8uswP8X
⚕Study 1️⃣ | Naldi et al. (2014): Randomized controlled trial on diet and physical exercise in psoriasis
⚕Study 2️⃣ | Katsimbri et al. (2021): Review on nutrition as a therapeutic tool for psoriasis and psoriatic arthritis